BACKGROUND: The annually recorded incidence of primary hepatic carcinomas has significantly increased over the past two decades accounting for over 800 thousand of annual deaths caused by hepatocellular carcinoma (HCC) alone globally. Further, secondary liver malignancies are much more widespread compared to primary hepatic carcinomas: almost all solid malignancies are able to metastasise into the liver. The primary tumours most frequently metastasising to the liver are breast followed by colorectal carcinomas. Given the increased incidence of both primary and metastatic liver cancers, a new, revised approach is needed to advance medical care based on predictive diagnostics, innovative screening programmes, targeted preventive measures, and patient stratification for treatment algorithms tailored to individualised patient profile. ADVANTAGES OF THE APPROACH TAKEN: The current pilot study took advantage of systemic alterations characteristic for liver malignancies, utilising liquid biopsy (blood samples) and specific biomarker patterns detected. Key molecular pathways relevant for pathomechanisms of liver cancers have been considered opening a perspective for both-individualised diagnostics and targeted treatment. Systemic alterations have been analysed prior to the therapy application avoiding molecular biological effects potentially diminishing predictive power of the biomarker-panel proposed. Multi-omics at DNA and protein (both expression and activity) levels has been applied. An established biomarker panel is considered as a powerful tool for individualised patient profiling and improved multi-level diagnostics-both predictive and prognostic ones. RESULTS AND CONCLUSIONS: Biomarker panels have been created for the patient stratification, prediction of a more optimal therapy and prognosis of survival based on the individualised patient profiling. Although there are some limitations of the pilot study performed, the results are encouraging, as it may be possible, through further research along these lines, to find a clinically and cost-effective means of stratifying liver cancer patients for personalised care and therapy. The benefits to the patient and society of accurate treatment stratification cannot be overemphasised.

Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Czech Republic

Breast Cancer Research Centre Rheinische Friedrich Wilhelms Universität Bonn Bonn Germany

Centre for Integrated Oncology Cologne Bonn Rheinische Friedrich Wilhelms Universität Bonn Bonn Germany

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Prague Czech Republic

Department of Neurology University Hospital Pilsen Pilsen Czech Republic

Department of Radiology Rheinische Friedrich Wilhelms Universität Bonn Sigmund Freud Str 25 53105 Bonn Germany

Interventional Radiology Department of Radiology New York Presbyterian Brooklyn Methodist Hospital Brooklyn NY USA

Zobrazit více v PubMed

Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Interv Radiol. 2006;23:47–63. doi: 10.1055/s-2006-939841. PubMed DOI PMC

Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527. doi: 10.1001/jamaoncol.2015.0735. PubMed DOI PMC

Duarte G, Williams CJ, Vasconcelos P, Nogueira P. Capacity to report on mortality attributable to chronic hepatitis B and C infections by member states: an exercise to monitor progress towards viral hepatitis elimination. J Viral Hepat. 2018;25:878–882. doi: 10.1111/jvh.12882. PubMed DOI

Golubnitschaja O, Sridhar KC. Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin Exp Metastasis. 2016;33:743–755. doi: 10.1007/s10585-016-9816-8. PubMed DOI

Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998;16:2105–2112. doi: 10.1200/JCO.1998.16.6.2105. PubMed DOI

Mokdad AA, Singal AG, Yopp AC. Advances in local and systemic therapies for hepatocellular cancer. Curr Oncol Rep. 2016;18:9. doi: 10.1007/s11912-015-0494-5. PubMed DOI

Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6:9. doi: 10.1186/s13167-015-0030-6. PubMed DOI PMC

Golubnitschaja O, Yeghiazaryan K, Stricker H, Trog D, Schild HH, Berliner L. Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer. 2016;16:357. doi: 10.1186/s12885-016-2382-2. PubMed DOI PMC

Hong Y-F, Chen Z-H, Wei L, Ma X-K, Li X, Wen J-Y, Wang TT, Cai XR, Wu DH, Chen J, Ruan DY, Lin ZX, Lin Q, Dong M, Wu XY. Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma. Oncol Lett. 2017;14:2089–2096. doi: 10.3892/ol.2017.6420. PubMed DOI PMC

Shen H, Zheng S, Chen R, Jin X, Xu X, Jing C, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: a retrospective analysis of 509 cases. Medicine (Baltimore) 2017;96:e7438. doi: 10.1097/MD.0000000000007438. PubMed DOI PMC

Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, Oi I, Fujino MA. Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transarterial chemoembolization. Oncology. 2016;91:317–330. doi: 10.1159/000448999. PubMed DOI

Soydal C, Keskin O, Kucuk ON, Ozkan E, Bilgic S, Idilman R, Kir MK. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. Ann Nucl Med. 2015;29:426–430. doi: 10.1007/s12149-015-0962-x. PubMed DOI

Kim SS, Cho HJ, Won JH, Bae JI, Kang DR, Lee J-D, Shin SJ, Lee KM, Yoo BM, Kim JK, Lee JH, Ahn SJ, Park JH, Cho SW, Cheong JY. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. Cytokine. 2015;76:449–457. doi: 10.1016/j.cyto.2015.07.001. PubMed DOI

Zhang X, Long Q. Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients. Medicine (Baltimore) 2017;96:e6694. doi: 10.1097/MD.0000000000006694. PubMed DOI PMC

Ma X-L, Jiang M, Zhao Y, Wang B-L, Shen M-N, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Cao Y, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Application of serum Annexin A3 in diagnosis, outcome prediction and therapeutic response evaluation for patients with hepatocellular carcinoma. Ann Surg Oncol. 2018;25:1686–1694. doi: 10.1245/s10434-018-6402-0. PubMed DOI

Margaritelis NV, Veskoukis AS, Paschalis V, Vrabas IS, Dipla K, Zafeiridis A, et al. Blood reflects tissue oxidative stress: a systematic review. Biomarkers. 2015;20:97–108. doi: 10.3109/1354750X.2014.1002807. PubMed DOI

Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012;11:2284–2293. doi: 10.1158/1535-7163.MCT-12-0093. PubMed DOI

Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. doi: 10.1186/1479-5876-9-171. PubMed DOI PMC

Teppo H-R, Soini Y, Karihtala P. Reactive oxygen species-mediated mechanisms of action of targeted cancer therapy. Oxid Med Cell Longev. 2017;2017:1485283. doi: 10.1155/2017/1485283. PubMed DOI PMC

Yang S-F, Chang C-W, Wei R-J, Shiue Y-L, Wang S-N, Yeh Y-T. Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int. 2014;2014:153867. PubMed PMC

Nishida N, Kudo M. Oxidative stress and epigenetic instability in human hepatocarcinogenesis. Dig Dis. 2013;31:447–453. doi: 10.1159/000355243. PubMed DOI

Mansoori AA, Jain SK. Molecular links between alcohol and tobacco induced DNA damage, gene polymorphisms and patho-physiological consequences: a systematic review of hepatic carcinogenesis. Asian Pac J Cancer Prev. 2015;16:4803–4812. doi: 10.7314/APJCP.2015.16.12.4803. PubMed DOI

Miller P, Kidwell KM, Thomas D, Sabel M, Rae JM, Hayes DF, Hudson BI, el-Ashry D, Lippman ME. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome. Breast Cancer Res Treat. 2017;166:85–94. doi: 10.1007/s10549-017-4366-6. PubMed DOI

Zhong J-M, Li J, Kang A-D, Huang S-Q, Liu W-B, Zhang Y, Liu ZH, Zeng L. Protein S100-A8: a potential metastasis-associated protein for breast cancer determined via iTRAQ quantitative proteomic and clinicopathological analysis. Oncol Lett. 2018;15:5285–5293. PubMed PMC

Moz S, Basso D, Bozzato D, Galozzi P, Navaglia F, Negm OH, Arrigoni G, Zambon CF, Padoan A, Tighe P, Todd I, Franchin C, Pedrazzoli S, Punzi L, Plebani M. SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells. Oncotarget. 2016;7:69927–69944. doi: 10.18632/oncotarget.12068. PubMed DOI PMC

De Ponti A, Wiechert L, Schneller D, Pusterla T, Longerich T, Hogg N, et al. A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett. 2015;369:396–404. doi: 10.1016/j.canlet.2015.09.005. PubMed DOI

Németh J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology. 2009;50(4):1251–1262. doi: 10.1002/hep.23099. PubMed DOI

Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res. 2000;21:867–876. doi: 10.1076/ceyr.21.5.867.5534. PubMed DOI

Golubnitschaja O, Filep N, Yeghiazaryan K, Blom HJ, Hofmann-Apitius M, Kuhn W. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids. 2018;50:383–395. doi: 10.1007/s00726-017-2524-0. PubMed DOI

Golubnitschaja O, Yeghiazaryan K, Abraham J-A, Schild HH, Costigliola V, Debald M, Kuhn W. Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes. Amino Acids. 2017;49:273–281. doi: 10.1007/s00726-016-2357-2. PubMed DOI

Golubnitschaja O, Moenkemann H, Kim K, Mozaffari MS. DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem Pharmacol. 2003;66:511–517. doi: 10.1016/S0006-2952(03)00285-5. PubMed DOI

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. PubMed DOI

Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. doi: 10.4103/jcar.JCar_9_16. PubMed DOI PMC

Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol. 2018;10:41–50. doi: 10.4254/wjh.v10.i1.41. PubMed DOI PMC

Stewart B, Wild C. World Cancer Report 2014 [Internet]. [cited 2018 May 28]. Available from: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014

Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G. Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumour Biol. 2016;37:12941–12957. doi: 10.1007/s13277-016-5168-x. PubMed DOI

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors associated with early mortality among patients with de novo metastatic breast cancer: a population-based study. Oncologist. 2017;22:386–393. doi: 10.1634/theoncologist.2016-0369. PubMed DOI PMC

Polivka J, Kralickova M, Polivka J, Kaiser C, Kuhn W, Golubnitschaja O. Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J. 2017;8:119–127. doi: 10.1007/s13167-017-0087-5. PubMed DOI PMC

Golubnitschaja O. Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J. 2017;8:17–22. doi: 10.1007/s13167-017-0086-6. PubMed DOI PMC

Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23. doi: 10.1186/s13167-016-0072-4. PubMed DOI PMC

Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008;8(4):243–252. doi: 10.2174/156800908784533445. PubMed DOI

Zha H, Sun H, Li X, Duan L, Li A, Gu Y, Zeng Z, Zhao J, Xie J, Yuan S, Li H, Zhou L. S100A8 facilitates the migration of colorectal cancer cells through regulating macrophages in the inflammatory microenvironment. Oncol Rep. 2016;36(1):279–290. doi: 10.3892/or.2016.4790. PubMed DOI

Reckenbeil J, Kraus D, Probstmeier R, Allam JP, Novak N, Frentzen M, Martini M, Wenghoefer M, Winter J. Cellular distribution and gene expression pattern of Metastasin (S100A4), Calgranulin A (S100A8), and Calgranulin B (S100A9) in oral lesions as markers for molecular pathology. Cancer Investig. 2016;34(6):246–254. doi: 10.1080/07357907.2016.1186172. PubMed DOI

Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles

Biobanks in the era of big data: objectives, challenges, perspectives, and innovations for predictive, preventive, and personalised medicine

The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases

Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm